All News

RheumNow Podcast square

RheumNow Podcast - RWCS 2022 Roundup (2.19.2022)

Jack Cush, MD

Drs. Jack Cush and Artie Kavanaugh review the highlights of the RWCS (Rheumatology Winter Clinical Symposium) from Maui.


Read Article
VitD_1.jpg

Vitamin D and the Risk of Autoimmune Diseases

Jack Cush, MD

The results of the VITAL study (presented at ACR 2021) are now published by BMJ, showing that vitamin D and omega 3 fatty acids reduce the overall risk of autoimmune disease (AID) in a population based intervention trial.

Read Article
RheumNow Podcast square

The Last Word on JAK Inhibitor Safety & 1133 Study (1.28.2022)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com.  This week a trifecta of Gout reports and the last word on the ORAL Surveillance study...

Read Article
risk2h.jpg

Risk vs. Benefit Lessons from the ORAL Surveillance Study

Jack Cush, MD

In an editorial in the current edition of the NEJM, Dr. Jasvinder Singh comments on the Oral Surveillance trial (Ytterberg et al.), a 4-year randomized, open-label, noninferiority, postauthorization, safety end-point trial, in high risk active rheumatoid arthritis patients over age 50 years.

Read Article
virus,COVID,Vaccine, booster

MMWR: Booster Vaccine Efficacy in Immunosuppressed Patients

CDC/MMWR

For adults aged ≥18 years who received 2 doses of an mRNA COVID-19 vaccine, a third dose increased vaccine effectiveness (prevention of hospitalization) among adults without (82% to 97%) and with immunocompromising conditions (69% to 88%), with near similar efficacy.

Read Article
FDA.approved.jpg

FDA Approves Skyrizi for Active Psoriatic Arthritis

Jack Cush, MD

On Friday, the U.S. Food and Drug Administration (FDA) approved risankizumab-rzaa (Skyrizi) for the treatment of adults with active psoriatic arthritis (PsA), with similar dosing in plaque psoriasis - a single 150mg subcutaneous injection four times a year after two starter doses (at weeks 0

Read Article
xray%20spine%20films_0.jpg

BE MOBILE 1 Study - Bimekizumab in Non-Radiographic Axial Spondyloarthritis

Jack Cush, MD

Today, UCB announced top-line interim analysis results from their Phase 3 "BE MOBILE 1" study, that demonstrated the efficacy of bimekizumab, a dual IL-17A and F inhibitor, in adults with active non-radiographic axial spondyloarthritis (nr-axSpA).

Read Article
COVID,vaccinate,injection,green

COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients

Jack Cush, MD

The EULAR Coronavirus Vaccine (COVAX) physician-reported registry has shown that the use of COVID-19 vaccines in people with inflammatory/autoimmune rheumatic and musculoskeletal disease (I-RMD) is effective, safe, and well tolerated.

Read Article
2021,year

2021 Rheumatology Year in Review

Jack Cush, MD

Our top 10 list of advances, game-changers, worries and those better medical practices that evolved during 2021.

Read Article
NOR-DRUM study shows that TDM, therapeutic drug monitoring, is beneficial. Study of RA, PSA, AS, Crohn's, UC Rheums don't do this, should they? #RWCS2022 @RWCSmtg https://t.co/Dc6mgr5jrL
Dr. John Cush RheumNow ( View Tweet)
ICYMI: Radiographic progression in AxSpA studied in 101 Spanish Pts - pts w/ sustained low ASDAS had less XRay progression than those with active Dz (2.33 vs 1.76, p=0.027). Long term TNFi use didnt influence progression until the 3rd Yr https://t.co/TchcLL2ivN

Links:

Dr. John Cush RheumNow ( View Tweet)

We have an exciting agenda for #RNL2022, with a pod on the Spondyloarthritis Spectrum and more , as well as speakers from around the world, including Dr. Jose Scher, who will lead a discussion on The Microbiome in Spondyloarthritis . Register Today! https://t.co/rZIrSzz6EN https://t.co/iGEN0hAKcg

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Peter Nigrovic asserts the division between pediatric and adult arthritis is senseless and has no firm biologic basis. Instead we should consider pts as sero- positive or negative, Systemci or Spondyloarthropathy. @UTSWRheum https://t.co/zx5oQmUQ6Y
Dr. John Cush RheumNow ( View Tweet)
UCB announced top-line interim analysis results from their Phase 3 "BE MOBILE 1" study, that demonstrated the efficacy of bimekizumab, a dual IL-17A and F inhibitor, in adults with active non-radiographic axial spondyloarthritis (nr-axSpA). https://t.co/FylgQ30Dva https://t.co/XJ4y0U60hu

Links:

Dr. John Cush RheumNow ( View Tweet)
Using SKG mouse model of adjuvant induced SpA and enthesitis, neutrophils, and inducible IL-23, were shown to play an important role in early murine spondyloarthritis-related enthesitis. https://t.co/wlHXkNbvR7

Links:

Dr. John Cush RheumNow ( View Tweet)

ASK CUSH ANYTHING! Have a Rheumatology question or case for Dr. Cush? Record it here and we may feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/LAC6XrYEyN https://t.co/POGHk7Ibq2

Links:

Dr. John Cush RheumNow ( View Tweet)
Why Are Physicians Silent About Outrageous Drug Prices? https://t.co/hLrUFCiKwm https://t.co/ZgRoW9Duo6

Links:

Dr. John Cush RheumNow ( View Tweet)
COVAX Registry: Safety of COVID-19 Vaccines in Rheum Patients  https://t.co/MrywKZKcIV https://t.co/QgajVPdesg

Links:

Dr. John Cush RheumNow ( View Tweet)
Register for RheumNow Live, March 19-20, 2022. You can attend RheumNow Live in person in Irving, Texas - or, the comfort of your own home or office. You can also receive CME credit! https://t.co/fYyV75vAWm https://t.co/zOpCbBrzHJ

Links:

Dr. John Cush RheumNow ( View Tweet)
ICYMI: Study of biologic/ts DMARD switching in 8,398 axial spondyloarthritis pts from 5 Nordic registries showed a low rate of multiple switches (refractory?) over 3 years; ≥3 DMARDs (8%), ≥4 (3%) & ≥ 5 (1%); more w/ women, comorbiditiy & psoriasis https://t.co/tc5D3Bwnnj

Links:

Dr. John Cush RheumNow ( View Tweet)

How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×